ReviewDisease models & mechanisms2020
Cell and animal models of SARS-CoV-2 pathogenesis and immunity.
Review in Disease models & mechanisms, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- The ACE2 Receptor from Common Vampire Bat (Viruses · 2025Article
- UltradilutedDiseases (Basel, Switzerland) · 2025Article
- Neutrophil adhesion to vessel walls impairs pulmonary circulation in COVID-19 pathology.Nature communications · 2025Article
- Development of a Mouse-Adapted Reporter SARS-CoV-2 as a Tool for Two-Photon In Vivo Imaging.Viruses · 2024Article
- Editorial: Model organisms in respiratory pharmacology 2023.Frontiers in pharmacology · 2024Article
- Organoids to Remodel SARS-CoV-2 Research: Updates, Limitations and Perspectives.Aging and disease · 2023Review
- Crossroads in virology: current challenges and future perspectives in the age of emerging viruses.Disease models & mechanisms · 2023Article
- Understanding the neurological implications of acute and long COVID using brain organoids.Disease models & mechanisms · 2023Review
- SARS-CoV-2 Inhibits NRF2-Mediated Antioxidant Responses in Airway Epithelial Cells and in the Lung of a Murine Model of Infection.Microbiology spectrum · 2023Article
- Susceptibility of SARS Coronavirus-2 infection in domestic and wild animals: a systematic review.3 Biotech · 2023Review
- Animal Models to Test SARS-CoV-2 Vaccines: Which Ones Are in Use and Future Expectations.Pathogens (Basel, Switzerland) · 2022Review
- PredictingACS omega · 2022Article
- Louis Pasteur continues to shape the future of microbiology.Disease models & mechanisms · 2022Article
- Differential Cell Line Susceptibility to the SARS-CoV-2 Omicron BA.1.1 Variant of Concern.Vaccines · 2022Article
- Frequent detection but lack of infectivity of SARS-CoV-2 RNA in presymptomatic, infected blood donor plasma.The Journal of clinical investigation · 2022Article
- Modelling infectious disease to support human health.Disease models & mechanisms · 2022Article
- Replication kinetics and infectivity of SARS-CoV-2 variants of concern in common cell culture models.Virology journal · 2022Article
- A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice.Science translational medicine · 2022Article
- Moxidectin and Ivermectin Inhibit SARS-CoV-2 Replication in Vero E6 Cells but Not in Human Primary Bronchial Epithelial Cells.Antimicrobial agents and chemotherapy · 2022Article
- Induced pluripotent stem cells: Generation methods and a new perspective in COVID-19 research.Frontiers in cell and developmental biology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The spread of the novel virus SARS coronavirus 2 (SARS-CoV-2) was explosive, with cases first identified in December 2019, and >22 million people infected and >775,000 deaths as of August 2020. SARS-CoV-2 can cause severe respiratory disease in humans leading to coronavirus disease 2019 (COVID-19). The development of effective clinical interventions, such as antivirals and vaccines that can limit or even prevent the burden and spread of SARS-CoV-2, is a global health priority. Testing of leading antivirals, monoclonal antibody therapies and vaccines against SARS-CoV-2 will require robust animal and cell models of viral pathogenesis. In this Special Article, we discuss the cell-based and animal models of SARS-CoV-2 infection and pathogenesis that have been described as of August 2020. We also outline the outstanding questions for which researchers can leverage animal and cell-based models to improve our understanding of SARS-CoV-2 pathogenesis and protective immunity. Taken together, the refinement of models of SARS-CoV-2 infection will be critical to guide the development of therapeutics and vaccines against SARS-CoV-2 to end the COVID-19 pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.